Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/65—Tetracyclines

Definitions

• the present invention relates to a pharmaceutical formulation in the form of a powder suitable for inhalation, to a process for making, and to its use in medicine.
• (DPI) treatments has been dominated by corticosteroid-based formulations and anticholinergic agents for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).
• active pharmaceutical ingredients APIs
• COPD Chronic Obstructive Pulmonary Disease
• APIs active pharmaceutical ingredients
• Formulation of these agents has employed a strategy whereby the API is blended .withxarriers,,. commonly lactose, aiding..deliyery.and dispersion of the API and., making it more processable. Examples of such formulations are available in the market.
• a growing body of treatments is emerging that requires high dose delivery, well into the milligram range and in some cases tens of milligrams.
• These emerging treatments include among others antibiotics for the treatment of cystic fibrosis, employing less potent, but perhaps more effective molecules than before.
• the step change in dosing levels required by these agents means that their effective delivery will require a fundamentally different approach to formulation design. Improvement of existing API/carrier based strategies will not be sufficient.
• these new formulations will require higher levels of API concentration, perhaps other substances to promote the penetration of the APTto the place where the action is needed, but without active effect, but that they will preferably be carrier- free (or. at least carrier reduced) in order to reach the dosing levels required.
• Elimination or reductions of carriers imposes new challenges for the efficient dispersion of APIs in a dry powder inhalation system.
• Appropriate selection of the particle processing technique is extremely important as efficient dispersion requires a particle size distribution that provides sufficient void space between particles to enhance air permeability and flight properties.
• US granted patent 6858199 discloses a high efficient method for the delivery of a large therapeutic mass aerosol: 'This method- comprises delivery of at least 50% of the mass of "aerodynarnically light" particles having a tap density of less than 0.4 g/cm3, comprising at least 1.0 milligrams of active agent contained in a receptacle having a volume of at least 0.37 cm 3 , which is bigger than the ones at the standard devices.
• This document teaches that until, now to achieve a high delivered dose of active the particles were required to have , a very., low density, and ..the ...formulation had to comprise carriers otherwise, aggregation would occur. Because of the low density and need of carrier the formulation had to be delivered from a. high volume receptacle (equivalent to capsules #2 and bigger).
• formulations combining antibiotics with mucolytic agents usually require the use of a carrier to deliver the formulation (see, for example, WO2012/2080700, GB 124221 1), which again limits the quantity of API that can be delivered.
• Efficiently dosing tens of milligrams of a large concentration of API formulation requires not only a fundamentally different formulation strategy but also a dry powder inhaler capable of holding and efficiently dispersing such a large mass of material.
• a pharmaceutical formulation in the form of a powder suitable for inhalation which formulation comprises one or more active pharmaceutical ingredients and a mucolytic agent and/or a buffer, wherein the formulation is free of carrier.
• the invention provides process for the manufacture of a formulation according to the invention comprising the step of suspending the active pharmaceutical ingredient in a solution of a buffer and/or a mucolytic agent. The powder can then be made therefrom, for example by drying, preferably by spray drying.
• a method for delivery of a formulation of the invention wherein the formulation is delivered from an inhaler having or being capable of holding a receptacle.
• the invention also provides a capsule comprising a formulation according the invention.
• an inhaler containing a formulation according to the invention.
• the invention als.o, s provides .a blister ot.blister strip .comprising r a,fprmulation according.io,. the invention.
• the invention provides a pharmaceutical formulation according to the invention for use as a medicament.
• This invention presents a high dose powder product suitable for inhalation where an active pharmaceutical ingredient or a mixture of two or more active pharmaceutical ingredients is delivered as a formulation consisting of an active pharmaceutical ingredient or a mixture of two or more active pharmaceutical ingredients and a buffer and/or a mucolytic agent or a buffer that preferably acts as a'mucolytic agent where the buffer can control the pH to . avoid damage to the lungs and the mucolytic agent facilitates the penetration of the API to the place of treatment.
• Dry powder inhalers include reservoir, capsule or blister inhalers or others.
• the total internal volume of the container should be in any case equal or less than 0.35 cm 3 .
• Benefits of this invention include the delivery by inhalation of a high dose formulation and including a buffer and/or a mucolytic agent packed in a regular size receptacle with no need of carrier, which leads to a lower amount of powder being delivered and in consequence to less side effects.
• free of carrier we mean that the formulation of the invention is free of conventional pharmaceutical carriers of the. type used as conventional API carriers in dry powder , formulations.
• One conventional carrier is lactose.
• the formulations of the invention are free, or essentially free, "o 'lactose.
• -The -formulations'-of 'the invention are also free, or essentially free, of other API carrier compounds.
• This ..invention ⁇ presents,.a -PatTier free formulation comprising an active pharmaceutical ingredient or a mixture of two or more active pharmaceutical ingredients and a mucolytic agent and/or a -buffer.
• a buffer is used without-a .separate mucolytic agent, it is preferred that the buffer acts as a mucolytic agent.
• the formulation consists essentially of one or more active pharmaceutical ingredients and a mucolytic agent and/or a buffer.
• the formulation consists of an active pharmaceutical ingredient or a mixture of two or more active pharmaceutical ingredients and a buffer.
• the buffer itself has mucolytic properties.
• mucolytic we mean an agent which helps dissolve mucous in the respiratory tract.
• a particularly preferred formulation of the invention uses a buffer which is a citrate compound, such as sodium citrate.
• a preferred formulation of the invention is where the active pharmaceutical ingredient or ingredients is doxycycline or a pharmaceutical acceptable salt thereof.
• a preferred formulation is one which consists essentially of doxycycline or a pharmaceutical acceptable salt thereof and a citrate buffer.
• the formulations of the invention are formulated so as to be capable of delivering a high dose, of .API to.,a patient.
• a high dose of .API to., a patient.
• th&XormuIation is.such that it is capable of delivering a dose of 5mg or more, of the one or more APIs.
• the active pharmaceutical ingredient or ingredients can be chosen from any active pharmaceutical; ingredients suitable for. delivery by inhalation, and examples include compounds 3 ⁇ 4ueh 3 ⁇ 4s "antibiotics, ' antivirals, steroids; bronchodilators, anticholinergics; enzymes, hormones, proteins, peptides and analgesics.
• the buffer can be any compound suitable for buffering in a DPI formulation, and is preferably a citrate or phosphate salt. Also, the buffer is ideally a mucolytic agent. Sodium citrate., is..a,preferred.. ⁇ to its buffering properties has the advantage of acting as a mucolytic agent. Alternatively a mucolytic agent that is not a buffer or a buffer that is not a mucolytic agent can be used.
• the buffer controls the pH to avoid damage to the lungs.
• the mucolytic agent facilitates the API penetration into the place of treatment.
• the mucolytic agent may be any agent with the required mucolytic activity, and that is suitable for use in a DPI formulation and is compatible with the other components of the formulation.
• suitable mucolytic agents include acebrophylline, acetylcysteine ,ambroxol, Bromhexine and its derivative brovanexine, carbocisteine, cyclidrol and sobrerol.
• the formulation can be used for the treatment of medical conditions in particular pulmonary diseases responsive to antibiotics such as cystic fibrosis and pulmonary bacterial or viral infections.
• the active pharmaceutical ingredient is an antibiotic, most preferably doxycycline, tobramycin, amoxylin, . vancomycin or phosphomycin or one of their salts or mixtures thereof.
• the formulation can be obtained by any suitable particle reduction method that will reduce the particle size of formulation constituents to a particle size suitable for inhalation.
• the active ingredients are then suspended in a solution of the mucolytic agent, and/or buffer and dried, for example by spray drying.
• the formulation can be filled in capsules suitable for a capsule based inhaler, or placed in the cavities of a reservoir inhaler or in the blisters of a blister inhaler or any other container suitable to be used with an inhaler.
• an individual dose will preferably be contained in a volume equal or less than 0.35 cm 3 .
• the formulation is then delivered by inhalation for the treatment of medical conditions in particular lung -diseases -such as cystic fibrosis.and.pulmQnary infections, among others ' .
• a process for the manufacture of a formulation according to the invention comprises the step of suspending the active pharmaceutical ingredient in a solution of a buffer and/or a mucolytic agent.
• the process may then further, comprise the step of isolating the formulation as a powder by drying. Preferably, spray drying is used.
• the powder after isolation maintains the same polymorphic form, and chemical purity, as that before isolation.
• the invention includes a method for delivery of a formulation of the invention wherein the formulation is delivered from an inhaler having or being capable of holding a receptacle.
• the inhaler is preferably a blister, a capsule or a reservoir inhaler.
• the formulation is delivered to a patient in need of one or more of the APIs, as will be understood.
• the receptacle preferably has a volume of equal to or less than 0.35 cm 3
• the delivered dose is preferably in the milligram range - that . is, . suitably lmg or .more. ofAPXis .delivered.. More preferably, at least 5 mg or more of API, suitably 1 Omg or more of API, is delivered.
• the mvention also provides a capsule comprising a formulation according to the invention.
• the "capsule- may 'be my'Suitable-DPI c ⁇ skilled in the art.
• the invention also provides an inhaler containing a formulation according to the invention, and this is preferably a dry powder inhaler.
• Suitable inhalers include a blister inhaler, a capsule.inhaler,JDr..a.r.eservoir inhaler.
• An inhaler aGCording-to .the nvention preferably deli-vers,.an «API-dose-of 5mg, or more.
• a blister or blister strip comprising a formulation of the invention may be used, as will be understood by those in the art.
• the invention includes a pharmaceutical formulation as . described herein for use as a medicament.
• a pharmaceutical formulation for use according to the invention delivers an API dose to a patient of 5mg or more.
• the dose delivered to a patient may be l Omg or more.
• the invention includes a pharmaceutical formulation as described herein for use in the treatment of pulmonary diseases, such as cystic fibrosis or a pulmonary infection.
• the ...formulation , strategy .. employed .eliminates Jhe xarrier and combines the antibiotic with sodium citrate, a buffer and known mucolytic agent to potentially increase the penetration capability of the antibiotic through the protective mucous layers that protect and inhibit antibiotic activity against pse domonas aeruginosa and other bacteria in the lungs'of cysticfibrosis'patients. ..
• the model high dose formulation was doxycycline monohydrate (80%), produced by jet- milling, combined with sodium citrate (20%).
• the sodium citrate was incorporated using spray drying of a doxycycline suspension in a sodium citrate solution.
• the resultant powder formulation was filled into TwinCaps® devices at two different trial fill weights .of.-50mg-and ..75mg-..powder in each of the 2 cavities that are smaller than- 0.35cm 3 .
• the delivered dose (DD), fine particle dose (FPD) and fine particle fraction (FPF) were then determined using a Fast Screening Impactor (FSI). FPD was classified as the amount of active material less than 5 ⁇ .
• Fine Particle Fractions a measure of dispersion efficiency, is in the order of 50% and similar for both fill weights.
• Figure 1 shows the results of the DD, and FPD of doxycycline per cavity for the two fill weights analyzed formulation (1).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Otolaryngology (AREA)
• Pulmonology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=47605587

Family Applications (1)

Country Status (2)

Cited By (8)

Citations (7)

Family Cites Families (4)

• 2012
  • 2012-01-13 PT PT106094A patent/PT106094A/pt not_active Application Discontinuation
• 2013
  • 2013-01-14 WO PCT/GB2013/000015 patent/WO2013104892A1/fr not_active Ceased

Patent Citations (7)

Also Published As

Similar Documents

Legal Events